Darzalex 100 mg Injection

Description

Darzalex 100 mg Injection contains daratumumab, a monoclonal antibody medicine used in the treatment of certain blood cancers, particularly multiple myeloma. It belongs to a class of medicines known as CD38-directed cytolytic antibodies, which target specific proteins found on the surface of cancerous plasma cells. By binding to these proteins, daratumumab helps the immune system identify and destroy malignant cells when used as prescribed by a qualified healthcare professional. Darzalex is typically administered as an intravenous infusion in a clinical setting by trained healthcare providers. It may be used alone or in combination with other anticancer medicines depending on the stage of disease and treatment plan recommended by an oncologist. Patients receiving this treatment are usually monitored through regular laboratory tests and medical evaluations to assess response and manage po

Benefits

• Targets CD38 proteins found on multiple myeloma cells

• Helps the immune system recognize and destroy malignant plasma cells

• Used in combination therapy regimens for multiple myeloma

• Administered under medical supervision in specialized oncology settings

• Part of modern immunotherapy approaches in hematologic cancers

Indications and Usage

Darzalex (daratumumab) may be prescribed for adults with:

• Multiple myeloma, including newly diagnosed cases in certain treatment regimens

• Relapsed or refractory multiple myeloma

• Use in combination with other anticancer medicines such as lenalidomide, bortezomib, dexamethasone, or pomalidomide depending on clinical protocols

Treatment decisions are based on disease stage, prior therapies, and patient health status.

How it Works

Daratumumab works by targeting CD38, a protein highly expressed on the surface of multiple myeloma cells. By binding to this protein, the medicine activates several immune-mediated mechanisms that help destroy cancer cells. These mechanisms include antibody-dependent cellular cytotoxicity, complement activation, and immune cell–mediated destruction.

In addition to directly targeting tumor cells, daratumumab may also influence immune system activity by affecting certain immune cell populations. This targeted immunotherapy approach helps the immune system recognize and eliminate malignant plasma cells when the medicine is administered as prescribed and monitored by an oncology specialist.

Dosage & Administration

• Darzalex is administered as an intravenous infusion in a hospital or oncology clinic.

• Infusions are given according to a treatment schedule determined by the oncologist.

• Initial infusions may take several hours and are administered under medical supervision.

• Premedications may be used to reduce the risk of infusion-related reactions.

• Treatment duration depends on clinical response, tolerance, and treatment protocol.

Side Effects

Common side effects

• Infusion-related reactions

• Fatigue

• Nausea

• Diarrhea or constipation

• Upper respiratory infections

• Decreased blood cell counts

Serious side effects

• Severe infusion reactions

• Low white blood cell counts increasing infection risk

• Severe infections

• Anemia or thrombocytopenia

• Interference with certain blood compatibility tests

Patients should seek medical attention if severe symptoms occur.

Warning and Precaution

• Risk of infusion-related reactions, particularly during the first infusion

• Possible low blood cell counts, requiring regular monitoring

• Increased risk of infections

• May interfere with blood compatibility testing (cross-matching)

• Inform healthcare providers before blood transfusions

• Pregnancy and breastfeeding considerations should be discussed with a healthcare professional

• Patients should inform doctors about all medications and supplements they are taking

Patient Guidance

• Treatment will be administered by healthcare professionals in a clinical setting

• Attend all scheduled infusion sessions and follow-up appointments

• Report symptoms such as fever, breathing difficulty, or unusual fatigue

• Inform healthcare providers if you require blood transfusions

• Maintain good hygiene and infection precautions during treatment

• Follow medical advice regarding monitoring tests and supportive care

Clinical Trial & Approvals

Daratumumab has been studied extensively in clinical trials for multiple myeloma. Studies such as the POLLUX, CASTOR, and MAIA trials demonstrated improved treatment outcomes when daratumumab was used in combination with other therapies. Based on these findings, daratumumab has received regulatory approvals from agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for several multiple myeloma treatment indications.

References

• U.S. Food and Drug Administration (FDA) – Darzalex Prescribing Information
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761036s041lbl.pdf

• European Medicines Agency (EMA) – Darzalex (daratumumab) Product Information
  https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex

• National Cancer Institute – Daratumumab Drug Information
  https://www.cancer.gov

• Drugs.com – Darzalex Drug Information
  https://www.drugs.com/darzalex.html

• ClinicalTrials.gov – Daratumumab Clinical Studies
  https://clinicaltrials.gov

Prescription & documentation note

Darzalex 100 mg Injection is typically supplied against a valid prescription and administered in a clinical setting. For international supply requests, patients may need to provide documentation such as a licensed physician’s prescription, medical records, and identification, depending on destination country regulations. MedsMonk may assist with documentation guidance where applicable.